Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Net Income | -10.84% | -19.50% | -22.26% | ||
| Total Depreciation and Amortization | -2.98% | -10.53% | -2.66% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -25.60% | -10.02% | 9.05% | ||
| Change in Net Operating Assets | -238.22% | 119.71% | 111.08% | ||
| Cash from Operations | -31.46% | 3.24% | -13.53% | ||
| Capital Expenditure | 50.58% | -487.38% | -720.59% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | 50.58% | -487.38% | -720.59% | ||
| Total Debt Issued | -- | -- | 49.70% | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 202,880.95% | -72.12% | 2,941.67% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | 15.82% | 75.00% | -- | ||
| Cash from Financing | 81.29% | 3,368.00% | 51.85% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 106.68% | 285.42% | 119.27% | ||